Nomura Global Growth Fund on Eli Lilly and Co.
Thesis
Eli Lilly outperformed on strong earnings results and guidance. The fund highlights the company's dominant GLP-1 franchise, including Mounjaro and Zepbound, and positive sentiment around the launch of the oral drug Foundayo. With GLP-1 pricing described as very affordable and Lilly holding dominant market share, the fund expects the company to benefit from the large opportunity over the next several years. Additional FDA approvals and drugs in areas such as Alzheimer's support the long-term growth case.
“expectations are high for the company to benefit from this large market opportunity over the next several years.”